Ovarian Genomics - Cancer PHGKB -

Specific PHGKB|Cancer|PHGKB

Ovarian Genomics

- Cancer PHGKB -

What's New

Last Posted: Nov 21, 2018

---

• A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.  
  Guo Wenna et al. Clinical epigenetics 2018 Nov 10(1) 142
• The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: high frequency of FANCM pathogenic variants.  
  Schubert Stephanie et al. International journal of cancer 2018 Nov
• A Recurrent BRCA2 Mutation Explains the Majority of Hereditary Breast and Ovarian Cancer Syndrome Cases in Puerto Rico.  
  Diaz-Zabala Hector J et al. Cancers 2018 Nov 10(11)
• Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations. 
  Ditchi Yoan et al. The breast journal 2018 Nov
• Population Based Testing for Primary Prevention: A Systematic Review.  
  Manchanda Ranjit et al. Cancers 2018 Nov 10(11)
• Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer.  
  Ladd Mary Kathleen et al. Translational behavioral medicine 2018 Nov
• A comprehensive gene mutation analysis of liquid biopsy samples from patients with metastatic colorectal cancer to the ovary: A case report.  
  Iwahashi Naoyuki et al. Oncology letters 2018 Nov 16(5) 6431-6436
• A retrospective study of extracolonic, non-endometrial cancer in Swedish Lynch syndrome families.  
  Karimi Masoud et al. Hereditary cancer in clinical practice 2018 1616
• Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC).  
  Hopper John L et al. Breast cancer research : BCR 2018 Nov 20(1) 132
• Best serum biomarker combination for ovarian cancer classification.  
  Song Hye-Jeong et al. Biomedical engineering online 2018 Nov 17(Suppl 2) 152